3.1 Growth Factors, Cytokines & Angiogenic Pathways

3.1 Growth Factors, Cytokines & Angiogenic Pathways

Core Clinical Principle: Wound healing is governed by an exquisitely coordinated network of soluble peptide signaling molecules: cytokines and growth factors. When chronic ulcers stall, it is rarely due to an isolated deficiency of a single peptide, but rather a catastrophic collapse of the molecular microenvironment—characterized by unrelenting pro-inflammatory cytokine expression, unrestrained matrix metalloproteinases (MMPs), and rapid enzymatic destruction of endogenous growth factors and their cell-surface receptors.

Wound healing is governed by an exquisitely coordinated network of soluble peptide signaling molecules: cytokines and growth factors. While these terms are frequently conflated, they occupy distinct biological and therapeutic niches in tissue regeneration:

• Cytokines (e.g., interleukins, interferons, tumor necrosis factor) are primarily immunomodulatory polypeptides synthesized by leukocytes, endothelial cells, and stromal cells. They act transiently in picomolar to nanomolar concentrations, functioning through paracrine, autocrine, and endocrine signaling to orchestrate inflammation, immune activation, and leukocyte trafficking.
• Growth Factors (e.g., PDGF, VEGF, FGF, EGF, TGF-β) are predominantly mitogenic and morphogenic polypeptides that stimulate cell proliferation, chemotaxis, directed differentiation, extracellular matrix (ECM) deposition, and vascularization. Growth factors signal predominantly through cell-surface receptor tyrosine kinases (RTKs) or serine/threonine kinase receptors.

In acute physiological repair, cytokine and growth factor signaling follows a tightly controlled temporal sequence. Conversely, chronic non-healing wounds (diabetic foot ulcers, venous leg ulcers, pressure injuries) display catastrophic dysregulation of this signaling network, characterized by persistent hyper-inflammation, uncontrolled proteolysis, and premature signaling degradation.

---

Platelet-Derived Growth Factor (PDGF) & Becaplermin Pharmacology

Platelet-Derived Growth Factor (PDGF) is among the earliest signals released following vascular injury. Stored within the alpha granules of platelets, PDGF is released into the provisional fibrin matrix upon platelet degranulation and is subsequently secreted by activated macrophages, vascular endothelial cells, and fibroblasts.

Isoforms and Receptor Specificity

PDGF exists as a dimeric glycoprotein composed of disulfide-linked polypeptide chains (chains A, B, C, and D). These assemble into five active dimeric isoforms:

• PDGF-AA, PDGF-BB, and PDGF-AB (classic isoforms)
• PDGF-CC and PDGF-DD (require extracellular proteolytic cleavage for activation)

PDGF mediates cellular effects by binding to two distinct transmembrane receptor tyrosine kinases: PDGFR-α and PDGFR-β. Ligand binding induces receptor dimerization:

• PDGFR-αα binds PDGF-AA, -BB, -AB, and -CC.
• PDGFR-ββ binds PDGF-BB and -DD with high affinity.
• PDGFR-αβ binds PDGF-AB, -BB, -CC, and -DD.

PDGF-BB is the universal ligand because it binds and activates all three dimeric receptor combinations (αα, ββ, αβ). PDGFR-β signaling is the predominant driver of mesenchymal cell chemotaxis, vascular smooth muscle cell migration, and pericyte recruitment during blood vessel stabilization.

Biological Actions in Wound Healing

1. Chemotaxis: Potent chemoattractant for circulating neutrophils, monocytes, and dermal fibroblasts to the wound site.
2. Mitogenesis: Strong mitogen for fibroblasts, vascular smooth muscle cells, and pericytes, driving granulation tissue expansion.
3. ECM Synthesis: Upregulates fibroblast synthesis of collagen types I and III, glycosaminoglycans, and proteoglycans.
4. Phenotypic Activation: Stimulates fibroblast remodeling and wound contraction via transition toward a proto-myofibroblastic phenotype.

Clinical Pharmacology: Becaplermin (Regranex 0.01% Gel)

Becaplermin is a recombinant human platelet-derived growth factor-BB (rhPDGF-BB) expressed in the yeast Saccharomyces cerevisiae. It is formulated as a 0.01% topical gel (100 mcg/g) and represents the only recombinant growth factor approved by the US FDA for wound care.

Clinical Pearl: The Becaplermin Malignancy Warning Was Removed

In 2008 the FDA added a boxed warning after a retrospective claims analysis found higher cancer mortality among patients dispensed 3 or more tubes of becaplermin. In November 2018 the FDA approved removal of that boxed warning after an extension of the original analysis and additional postmarketing studies (including a large Veterans Affairs cohort) did not show increased cancer incidence or cancer mortality. Because PDGF is a mitogen, the label still contraindicates use when a neoplasm is present at the application site, and prudent prescribers avoid it when a malignancy is suspected. Outdated review materials may still describe the boxed warning—know that it no longer applies.

---

Vascular Endothelial Growth Factor (VEGF) & Angiogenic Signaling

Angiogenesis—the sprouting of new capillary blood vessels from pre-existing vasculature—is obligatory for granulation tissue formation. The primary orchestrator of this process is Vascular Endothelial Growth Factor-A (VEGF-A).

The Hypoxia-Inducible Factor 1-alpha (HIF-1α) Axis

Under physiologic tissue normoxia, cells continuously synthesize Hypoxia-Inducible Factor 1-alpha (HIF-1α), but it is immediately marked for destruction:

1. Normoxia: Prolyl Hydroxylase Domain (PHD 1–3) enzymes utilize molecular oxygen (O2), ferrous iron (Fe2+), and 2-oxoglutarate (alpha-ketoglutarate) to hydroxylate specific proline residues (Pro402 and Pro564) within the oxygen-dependent degradation domain of HIF-1α.
2. Ubiquitination: Hydroxylated HIF-1α is recognized by the von Hippel-Lindau (VHL) tumor suppressor protein, which serves as the recognition component of an E3 ubiquitin ligase complex. VHL polyubiquitinates HIF-1α, directing it to the 26S proteasome for rapid proteolytic degradation (half-life < 5 minutes).
3. Hypoxia (tissue pO2 < 30 mmHg): Oxygen depletion deprives PHD enzymes of their essential co-substrate. Hydroxylation ceases, allowing HIF-1α to stabilize and accumulate within the cytoplasm.
4. Transcriptional Activation: Stabilized HIF-1α translocates into the nucleus, heterodimerizes with constitutively expressed HIF-1β (ARNT), and recruits co-activators p300/CBP. This complex binds Hypoxia Response Elements (HRE; 5′-RCGTG-3′) in the promoter regions of target genes, robustly driving transcription of VEGF-A, erythropoietin, inducible nitric oxide synthase (iNOS), and glucose transporters (GLUT-1).

Normoxia (pO2 > 40 mmHg):   HIF-1α + O2 + Fe2+ + 2-Oxoglutarate 
                              ──(PHD enzymes)──> Hydroxylated HIF-1α 
                              ──(pVHL E3 Ligase)──> Polyubiquitination 
                              ──(26S Proteasome)──> Rapid Degradation

Hypoxia (pO2 < 30 mmHg):    PHD Inactivation ──> HIF-1α Accumulation & Nuclear Import 
                              ──(+ HIF-1β)──> Binds HRE Promoters 
                              ──> Massive Upregulation of VEGF-A & Glycolysis Genes

VEGF Receptors and Endothelial Tip-Stalk Dynamics

VEGF-A exists in multiple splice variants (VEGF121, VEGF165, VEGF189, VEGF206), with VEGF165 being the predominant biological driver of tissue vascularization:

• VEGFR-1 (Flt-1): High affinity for VEGF-A, but weak tyrosine kinase activity; functions largely as a "decoy" receptor to regulate local ligand availability.
• VEGFR-2 (KDR/Flk-1): The principal transducer of angiogenic signaling. Upon VEGF-A binding, VEGFR-2 undergoes homodimerization and autophosphorylation on cytoplasmic tyrosine residues (Tyr1175, Tyr1214), activating downstream cascades:
  • PLCγ–IP3/DAG–PKC–Raf–MEK–ERK: Stimulates endothelial cell proliferation.
  • PI3K–Akt–eNOS: Promotes endothelial survival, nitric oxide production, and vasodilation.
  • p38 MAPK–HSP27: Drives actin cytoskeletal reorganization and endothelial migration.
  • Vascular Permeability: Historically designated vascular permeability factor (VPF), VEGFR-2 activation disrupts VE-cadherin at endothelial adherens junctions, inducing plasma extravasation to deposit a fibrin provisional matrix.
• Tip Cell vs. Stalk Cell Selection: VEGF-A gradients induce endothelial tip cells (which extend filopodia and lead vessel sprouts) via VEGFR-2. Tip cells upregulate the Notch ligand Delta-like ligand 4 (Dll4), which binds Notch-1 receptors on adjacent trailing cells, downregulating their VEGFR-2 expression and converting them into proliferating stalk cells that establish the vascular lumen.

---

Transforming Growth Factor-Beta (TGF-β) Superfamily: Fibrosis vs. Scarless Healing

The Transforming Growth Factor-beta (TGF-β) superfamily controls immune suppression, mesenchymal cell activation, ECM deposition, and tissue remodeling. TGF-β is synthesized in an inactive latent form comprising the active cytokine dimer non-covalently linked to the Latency-Associated Peptide (LAP), which is covalently anchored to the ECM via Latent TGF-β Binding Protein (LTBP). Latent TGF-β must be activated extracellularly by proteases (plasmin, MMP-2, MMP-9), thrombospondin-1, or integrins (αvβ6, αvβ8).

Isoform Divergence: TGF-β1, TGF-β2, and TGF-β3

Three distinct mammalian isoforms exist, each binding transmembrane serine/threonine kinase receptors (TGF-βRII and TGF-βRI/ALK-5) to phosphorylate receptor-regulated Smads (Smad2 and Smad3), which complex with common-mediator Smad4 and translocate to the nucleus.

The Fetal Scarless Healing Paradigm

Early-gestation mammalian fetuses (first and second trimesters) heal cutaneous excisional wounds without macroscopic scar formation, characterized by:

1. A high ratio of TGF-β3 to TGF-β1/β2 (adult wounds display high TGF-β1/β2 and low TGF-β3).
2. A blunted, transient inflammatory response with minimal neutrophil and macrophage infiltration.
3. Rapid deposition of Type III collagen organized in a fine basket-weave pattern identical to uninjured dermis, in contrast to the dense, parallel, disorganized Type I collagen bundles of adult fibrotic scars.

---

Additional Crucial Growth Factors: FGF, EGF, and KGF

Fibroblast Growth Factor (FGF) Family

The FGF family encompasses 22 structurally related polypeptides that bind transmembrane RTKs (FGFR1–FGFR4). Heparan sulfate proteoglycans (HSPGs) on the cell surface and ECM serve as obligatory co-receptors:

• Basic Fibroblast Growth Factor (bFGF / FGF-2): Synthesized by endothelial cells, macrophages, and fibroblasts. Potent broad-spectrum mitogen and chemoattractant for vascular endothelial cells, fibroblasts, and smooth muscle cells. Drives vigorous capillary sprouting and granulation tissue development.
• Acidic Fibroblast Growth Factor (aFGF / FGF-1): Promotes neurovascular repair, endothelial proliferation, and dermal matrix remodeling.
• Keratinocyte Growth Factor (KGF / FGF-7) & FGF-10: Synthesized exclusively by stromal dermal fibroblasts, but acts exclusively through the FGFR2b splice variant expressed on basal keratinocytes. This paracrine stromal-epithelial loop stimulates keratinocyte proliferation and lateral migration across the wound bed without stimulating dermal fibroblasts.

Epidermal Growth Factor (EGF) & Transforming Growth Factor-Alpha (TGF-α)

• EGF (from platelets and submaxillary glands) and TGF-α (from keratinocytes and macrophages) bind the Epidermal Growth Factor Receptor (EGFR / HER1 / ErbB1).
• EGFR activation induces hemidesmosome disassembly (via phosphorylation of integrin α6β4), allowing basal keratinocytes to detach from the basement membrane and migrate laterally across the granulation bed (epiboly).
• Promotes keratinocyte survival, upregulates MMP-1 (collagenase-1) to cleave collagen obstacles in the migratory path, and stimulates epidermal re-stratification.

---

Pro-inflammatory vs. Anti-inflammatory Cytokine Balance

+-------------------------------------------------------------------------+
|                    CYTOKINE POLARIZATION IN REPAIR                      |
+-------------------------------------------------------------------------+
| PRO-INFLAMMATORY (M1 Macrophages, Neutrophils):                         |
|   * TNF-alpha, IL-1beta, IL-6                                           |
|   * Downstream: NF-kappaB, AP-1 activation                              |
|   * Biological Effect: Clears debris/pathogens, elevates MMPs          |
|   * Chronic Wound State: Sustained hyper-elevation -> Matrix destruction|
+-------------------------------------------------------------------------+
| ANTI-INFLAMMATORY (M2 Macrophages, Regulatory T-Cells):                 |
|   * IL-10, IL-1Ra                                                       |
|   * Downstream: STAT3 activation, competitive IL-1R1 blockade           |
|   * Biological Effect: Resolves inflammation, suppresses NF-kappaB      |
|   * Chronic Wound State: Severe deficiency -> Failure to resolve        |
+-------------------------------------------------------------------------+

The Pro-Inflammatory Triad: TNF-α, IL-1β, and IL-6

• Tumor Necrosis Factor-alpha (TNF-α): Produced by M1-polarized macrophages and neutrophils. At low concentrations, it stimulates macrophage growth factor synthesis and angiogenesis. At persistent high concentrations (as in chronic wounds), it activates NF-κB, suppresses collagen synthesis, and triggers mass transcription of MMP-1, MMP-8, MMP-9, and MMP-13.
• Interleukin-1 beta (IL-1β): Cleaved by the NLRP3 inflammasome (caspase-1). Stimulates vascular adhesion molecules (ICAM-1, VCAM-1, E-selectin), promoting ongoing leukocyte extravasation and driving local proteolysis.
• Interleukin-6 (IL-6): Drives transition from neutrophilic to mononuclear infiltration; induces acute-phase protein synthesis and regulates keratinocyte mitogenesis.

The Counter-Regulatory Network: IL-10 & IL-1Ra

• Interleukin-10 (IL-10): Secreted by M2 pro-healing macrophages and regulatory T-cells (Tregs). Activates STAT3 signaling to downregulate MHC-II and costimulatory molecules, suppresses macrophage transcription of TNF-α and IL-1β, and halts neutrophil oxidative burst.
• Interleukin-1 Receptor Antagonist (IL-1Ra): Competitively binds to IL-1R1 without recruiting the IL-1RAcP coreceptor, blocking IL-1 signaling without activating downstream transcription.

The Chronic Wound Proteolytic Trap

In chronic wounds (DFUs, VLUs), this cytokine switch fails completely. Trapped in a persistent, unresolved inflammatory phase, high levels of TNF-α and IL-1β elevate inflammatory proteases (MMP-1, MMP-8, MMP-9, and human neutrophil elastase) to many times normal healing levels. These uninhibited proteases cleave:

1. Endogenous and exogenously applied growth factors (PDGF, VEGF, EGF).
2. Cell surface growth factor receptors (PDGFR, VEGFR, EGFR).
3. Fibronectin, vitronectin, and provisional ECM scaffolding.

Consequently, applying topical growth factors to a contaminated, inflamed, non-debrided wound bed is entirely futile because the therapeutic molecules are enzymatically destroyed within minutes.